AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. The post AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug appeared first on MedCity News.

In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies. The post MedCity Pivot Podcast: A Conversation With AliveCor’s Priya Abani appeared first on MedCity News.

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation The post The Illegal Drug Marketplace in Your Patients’ Pockets appeared first on MedCity News.

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections. The post DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens appeared first on MedCity News.

The Association for Direct Care launched a coalition focused on expanding direct contracting to lower healthcare costs. The post New Coalition Launches to Expand Direct Contracting appeared first on MedCity News.

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology. The post Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch appeared first on MedCity News.

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment. The post Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care appeared first on MedCity News.

[Sponsored] Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats? The post Hospital and Payer AI Governance Is at a Crossroads appeared first on MedCity News.

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?  The post When AI Gets Medicine Wrong, Who’s Liable? appeared first on MedCity News.

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change. The post Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need appeared first on MedCity News.

What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.   The post MedTech Commercialization Gap: Moving Beyond Technical Viability  appeared first on MedCity News.

When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices. The post Report: High Drug Costs Are Creating Hidden Burden for Physicians appeared first on MedCity News.

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration. The post Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut appeared first on MedCity News.

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care.  The post AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start appeared first on MedCity News.